Assay
Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| National Vision Holdings, Inc.EYE · healthcare | |
|---|---|
| Grade |  Eweakest fifth of 371 graded peers; percentile 86.2, sampling error 2.5 points; lower is stronger |
| Rank | 320 of 371 |
| Profitability | C/Dpercentile 61.5 |
| Solvency | Epercentile 93.6 |
| Growth and financing | Bpercentile 36.6 |
| Reliability | 0.91 AUCfailure model, filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025 |
| Peer failure rate | 1.01% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | $591M to $2.67B assetstotal assets $2.0B[1] |
| Standard universe | insiderevenue above $1M and assets above $10M[1-2] |
| Warnings | none activenot computable: distress |
| Inputs computable | 7 of 14 |
| Graded from | filings received through Mar 4, 2026219 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $16.722026-10-08; market equity $1.3B; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Mar 4, 2026; the document on sec.gov.
National Vision Holdings, Inc., a Delaware corporation, and its consolidated subsidiaries are referred to here as “we,” “our,” “us,” “the Company,” or “National Vision.” National Vision Holdings, Inc. conducts substantially all of its activities through its indirect, wholly-owned subsidiary, National Vision, Inc. (“NVI”), and NVI’s subsidiaries. We operate under one reportable segment, our Owned & Host segment, which includes our two owned brands, America’s Best Contacts and Eyeglasses (“America’s Best”) and Eyeglass World, as well as our Host brands, Vista Optical locations within select Fred Meyer stores and Vista Optical locations on select military bases. See Part II. Item 8. Note 15.
The Fourteen Inputs [top]
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 61.5 | |||||||
| Gross profitability | not computable | 32.2% | |||||
| latest aligned inputs end 2018-12-29; latest annual assets end 2026-01-03 | |||||||
| Return on invested capital | 4.1% | [3-11] | 9.3% | 64.4 | 74 | 2026-01-03 | |
| Accruals ratio | (5.8%) | [1,12-14] | (6.6%) | 58.6 | 811 | 2026-01-03 | |
| Gross margin stability, five years | not computable | 2.8 pts | |||||
| five annual gross margins are required; found 2 | |||||||
| Solvency, sleeve percentile 93.6 | |||||||
| Twelve-month failure probability | not computable | 0.07% | |||||
| liabilities and a nearby cover-page share count are required at 2026-07-04 | |||||||
| Altman Z double-prime | not computable | (0.31) | |||||
| one or more required annual facts are missing | |||||||
| Net debt to EBITDA | not computable | 1.82x | |||||
| latest aligned inputs end 2017-12-30; latest annual assets end 2026-01-03 | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| latest aligned inputs end 2017-12-30; latest annual assets end 2026-01-03 | |||||||
| Current ratio | 0.55x | [15-16] | 2.96x | 93.6 | 839 | 2026-01-03 | |
| Growth and financing, sleeve percentile 36.6 | |||||||
| Revenue growth, three-year compound | 6.5% | [2,17-19] | 10.0% | 56.3 | 415 | 2026-01-03 | |
| Free cash flow growth, three-year compound | 135.1% | [13,20-26] | 10.9% | 5.3 | 96 | 2026-01-03 | |
| Reinvestment rate | not computable | 37.1% | |||||
| a prior annual working-capital observation is required | |||||||
| Asset growth, three years | (4.7%) | [1,14,27-28] | 2.1% | 61.7 | 704 | 2026-01-03 | |
| Net share issuance, one year | 0.8% | [29-30] | 2.5% | 23.2 | 634 | 2026-02-20 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Sleeves are equal-weighted; within a sleeve each computable input carries equal weight. Composite 0.309; sampling error 2.5 percentile points on 371 peers.
Among 371 Peers [top]
Composite score of every graded peer, smoothed. Vertical rules are the letter band edges at the 20th, 40th, 60th and 80th percentiles. Small dots are the six largest peers by market equity.
| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 315 | Journey Medical Corp. (DERM) Journey Medical Corp. (DERM) Eweakest fifth; percentile 84.9 Nasdaq · Pharmaceutical Preparations market equity $68.8M; last close $5.95 No active warnings; 7 of 14 inputs | 84.9 | E | |
| 316 | Amgen Inc. (AMGN) Amgen Inc. (AMGN) Eweakest fifth; percentile 85.1 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $220.3B; last close $407.41 No active warnings; 11 of 14 inputs | 85.1 | E | |
| 317 | Organon & Co. (OGN) Organon & Co. (OGN) Eweakest fifth; percentile 85.4 NYSE · Pharmaceutical Preparations market equity $3.6B; last close $13.76 No active warnings; 8 of 14 inputs | 85.4 | E | |
| 318 | Sonoma Pharmaceuticals, Inc. (SNOA) Sonoma Pharmaceuticals, Inc. (SNOA) Eweakest fifth; percentile 85.7 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $5.6M; last close $1.17 Warnings: dilution, fortress balance sheet; 8 of 14 inputs | 85.7 | E | dilution, fortress balance sheet |
| 319 | Outset Medical, Inc. (OM) Outset Medical, Inc. (OM) Eweakest fifth; percentile 85.9 Nasdaq · Electromedical & Electrotherapeutic Apparatus market equity $76.9M; last close $4.08 Warnings: dilution; 10 of 14 inputs | 85.9 | E | dilution |
| 320 | National Vision Holdings, Inc. (EYE) National Vision Holdings, Inc. (EYE) Eweakest fifth; percentile 86.2 Nasdaq · Ophthalmic Goods market equity $1.3B; last close $16.72 No active warnings; 7 of 14 inputs | 86.2 | E | |
| 321 | Natural Alternatives International Inc. (NAII) Natural Alternatives International Inc. (NAII) Eweakest fifth; percentile 86.5 Nasdaq · Medicinal Chemicals & Botanical Products market equity $25.3M; last close $1.17 Warnings: dilution, late filer, fortress balance sheet; 8 of 14 inputs | 86.5 | E | dilution, late filer, fortress balance sheet |
| 322 | DarioHealth Corp. (DRIO) DarioHealth Corp. (DRIO) Eweakest fifth; percentile 86.8 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $53.2M; last close $5.61 Warnings: dilution, short runway; 7 of 14 inputs | 86.8 | E | dilution, short runway |
| 323 | Intellia Therapeutics, Inc. (NTLA) Intellia Therapeutics, Inc. (NTLA) Eweakest fifth; percentile 87.0 Nasdaq · In Vitro & In Vivo Diagnostic Substances market equity $1.8B; last close $12.59 Warnings: short runway; 7 of 14 inputs | 87.0 | E | short runway |
| 324 | Heron Therapeutics, Inc. (HRTX) Heron Therapeutics, Inc. (HRTX) Eweakest fifth; percentile 87.3 Nasdaq · Pharmaceutical Preparations market equity $68.0M; last close $0.36 Warnings: distress; 9 of 14 inputs | 87.3 | E | distress |
| 325 | Lexaria Bioscience Corp. (LEXX) Lexaria Bioscience Corp. (LEXX) Eweakest fifth; percentile 87.6 Nasdaq · Pharmaceutical Preparations market equity $5.3M; last close $3.37 Warnings: dilution, short runway, distress; 9 of 14 inputs | 87.6 | E | dilution, short runway, distress |
| Peer policy | Letter | Percentile | Peers |
|---|---|---|---|
| all graded filers, equal sleeves | E | 89.1 | 2204 |
| sector peers, equal sleeves (the grade) | E | 86.2 | 371 |
| same exchange, equal sleeves | E | 85.3 | 1219 |
| sector peers, equal inputs | D | 63.0 | 371 |
Each letter is one fifth of the 371 graded peers, about 74 companies. A boundary letter (A/B, B/C, C/D, D/E) marks a percentile within one sampling error of a band edge.
What the Price Implies [top]
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | (41.5%) | 8.0% | 17 | hotter than 17 of 100 peers |
| Distance from 52-week high | (43.2%) | (31.4%) | 34 | closer to its high than 34 of 100 peers |
| EBIT to enterprise value | 3.9% | (1.5%) | 71 | pricier than 29 of 100 peers |
| Free cash flow yield | 5.5% | (1.0%) | 84 | pricier than 16 of 100 peers |
| Book value to price | 0.68 | 0.28 | 76 | pricier than 24 of 100 peers |
| Sales to price | 1.50 | 0.31 | 87 | pricier than 13 of 100 peers |
| Composite equity issuance, five years | (2.8%) | 20.3% | 23 | more equity-funded than 23 of 100 peers |
| Relative strength against the sector, log excess return | (0.75) | (0.14) | 17 | ahead of 17 of 100 peers |
Inputs: market equity $1.3B; EBIT $58.8M; free cash flow $73.5M; book equity $897.0M; sales $2.0B; debt $221.3M; cash $36.0M[31].
Diagnostics [top]
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2026-01-03 | ||
|---|---|---|
| Return on assets above zero | 1.5% | ✓ pass[12,14] |
| Operating cash flow above zero | $146.3M | ✓ pass[13] |
| Return on assets improved | 2.8 pts | ✓ pass[12,14,27,32] |
| Operating cash flow exceeds net income | $116.7M | ✓ pass[12-13] |
| Long-term leverage fell | (0.3 pts) | ✓ pass[1,14,27,33-34] |
| Current ratio improved | 1.4 pts | ✓ pass[15-16,35-36] |
| No new shares issued | 0.8% | ✗ fail[29-30] |
| Gross margin improved | n/a | |
| Asset turnover improved | 15.1 pts | ✓ pass[2,14,17,27] |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | $36.0M[37] |
| Operating cash flow, four quarters | $129.6M[13,37-41] |
| Months of runway | not finite |
| trailing operating cash flow is nonnegative, so runway is not finite | |
| Late filings, two years | 0 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 57 |
| 10-Q received Aug 13, 2026 | |
| Median daily dollar volume | $37.2M |
| 63 sessions | |
| Days since newest grade input | 219 |
Downloads [top]
|
Sources [top]
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $2.0B | 2026-01-03 | 2026-03-04 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $2.0B | 2026-01-03 | 2026-03-04 | 10-K | filing · viewer · series |
| 3 | operating income | us-gaap:OperatingIncomeLoss | $58.8M | 2026-01-03 | 2026-03-04 | 10-K | filing · viewer · series |
| 4 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | $41.7M | 2026-01-03 | 2026-03-04 | 10-K | filing · viewer · series |
| 5 | income tax | us-gaap:IncomeTaxExpenseBenefit | $12.1M | 2026-01-03 | 2026-03-04 | 10-K | filing · viewer · series |
| 6 | total debt | us-gaap:LongTermDebtAndCapitalLeaseObligations | $229.3M | 2026-01-03 | 2026-03-04 | 10-K | filing · viewer · series |
| 7 | book equity | us-gaap:StockholdersEquity | $869.5M | 2026-01-03 | 2026-03-04 | 10-K | filing · viewer · series |
| 8 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $38.7M | 2026-01-03 | 2026-03-04 | 10-K | filing · viewer · series |
| 9 | total debt | us-gaap:LongTermDebtAndCapitalLeaseObligations | $248.6M | 2024-12-28 | 2026-03-04 | 10-K | filing · viewer · series |
| 10 | book equity | us-gaap:StockholdersEquity | $816.3M | 2024-12-28 | 2026-03-04 | 10-K | filing · viewer · series |
| 11 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $73.9M | 2024-12-28 | 2026-03-04 | 10-K | filing · viewer · series |
| 12 | net income | us-gaap:NetIncomeLoss | $29.6M | 2026-01-03 | 2026-03-04 | 10-K | filing · viewer · series |
| 13 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $146.3M | 2026-01-03 | 2026-03-04 | 10-K | filing · viewer · series |
| 14 | assets | us-gaap:Assets | $2.0B | 2024-12-28 | 2026-03-04 | 10-K | filing · viewer · series |
| 15 | current assets | us-gaap:AssetsCurrent | $225.7M | 2026-01-03 | 2026-03-04 | 10-K | filing · viewer · series |
| 16 | current liabilities | us-gaap:LiabilitiesCurrent | $412.4M | 2026-01-03 | 2026-03-04 | 10-K | filing · viewer · series |
| 17 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $1.8B | 2024-12-28 | 2026-03-04 | 10-K | filing · viewer · series |
| 18 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $1.8B | 2023-12-30 | 2026-03-04 | 10-K | filing · viewer · series |
| 19 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $1.6B | 2022-12-31 | 2025-02-26 | 10-K | filing · viewer · series |
| 20 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $72.8M | 2026-01-03 | 2026-03-04 | 10-K | filing · viewer · series |
| 21 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $133.6M | 2024-12-28 | 2026-03-04 | 10-K | filing · viewer · series |
| 22 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $95.5M | 2024-12-28 | 2026-03-04 | 10-K | filing · viewer · series |
| 23 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $173.0M | 2023-12-30 | 2026-03-04 | 10-K | filing · viewer · series |
| 24 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $114.8M | 2023-12-30 | 2026-03-04 | 10-K | filing · viewer · series |
| 25 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $119.2M | 2022-12-31 | 2025-02-26 | 10-K | filing · viewer · series |
| 26 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $113.5M | 2022-12-31 | 2025-02-26 | 10-K | filing · viewer · series |
| 27 | assets | us-gaap:Assets | $2.2B | 2023-12-30 | 2025-02-26 | 10-K | filing · viewer · series |
| 28 | assets | us-gaap:Assets | $2.3B | 2022-12-31 | 2024-02-27 | 10-K | filing · viewer · series |
| 29 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 79,437,185 | 2026-02-20 | 2026-03-04 | 10-K | filing · viewer · series |
| 30 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 78,783,482 | 2025-02-14 | 2025-02-26 | 10-K | filing · viewer · series |
| 31 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 79,069,313 | 2026-07-31 | 2026-08-13 | 10-Q | filing · viewer · series |
| 32 | net income | us-gaap:NetIncomeLoss | -$28.5M | 2024-12-28 | 2026-03-04 | 10-K | filing · viewer · series |
| 33 | long term debt | us-gaap:LongTermDebtNoncurrent | $223.2M | 2026-01-03 | 2026-03-04 | 10-K | filing · viewer · series |
| 34 | long term debt | us-gaap:LongTermDebtNoncurrent | $239.1M | 2024-12-28 | 2026-03-04 | 10-K | filing · viewer · series |
| 35 | current assets | us-gaap:AssetsCurrent | $249.8M | 2024-12-28 | 2026-03-04 | 10-K | filing · viewer · series |
| 36 | current liabilities | us-gaap:LiabilitiesCurrent | $468.3M | 2024-12-28 | 2026-03-04 | 10-K | filing · viewer · series |
| 37 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $36.0M | 2026-07-04 | 2026-08-13 | 10-Q | filing · viewer · series |
| 38 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $69.8M | 2026-07-04 | 2026-08-13 | 10-Q | filing · viewer · series |
| 39 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $61.7M | 2026-04-04 | 2026-05-14 | 10-Q | filing · viewer · series |
| 40 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $133.1M | 2025-09-27 | 2025-11-06 | 10-Q | filing · viewer · series |
| 41 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $86.5M | 2025-06-28 | 2026-08-13 | 10-Q | filing · viewer · series |
Limitations [top]
Grade boundary. Percentile 86.2 is 6.2 points from the nearest band edge; sampling error is 2.5 points.
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
